Doug Drysdale on Psychedelics: The Future of Mental Health Treatment
We get to talk about words like cure and not just mitigate or make it a little bit better. I think science leading the way is the right way to go.
Imagine a future where psychedelics are a standard part of mental health treatment. In this episode of the Stigma Podcast, host Stephen Hays sits down with Doug Drysdale, the CEO of Cybin, to explore this exciting possibility. Cybin is at the forefront of developing mushroom-based psychedelic and non-psychedelic products aimed at treating psychiatric and neurological conditions. With over 30 years of experience in healthcare, Doug brings a wealth of knowledge and a fresh perspective to the conversation.
From his journey through the pharmaceutical industry to leading Cybin, Doug shares how his career path has led him to embrace the potential of psychedelics in medicine. The discussion dives into the science behind low-dose psychedelics, the innovative delivery systems Cybin is developing, and the promising results from early clinical trials. For anyone curious about the intersection of mental health and cutting-edge treatments, this episode offers a deep dive into what could be the next big breakthrough.
Whether you're an investor, a mental health professional, or someone looking for new avenues of hope, Doug's insights provide a compelling look at what the future might hold.